Results 11 to 20 of about 16,492 (195)
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome [PDF]
Diabetes & Metabolism Journal, 2018 BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor.
Kwi-Hyun Bae +11 more
doaj +1 more source
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism [PDF]
Current Opinion in Lipidology, 2019 Purpose of review The purpose of this review is to highlight the recent findings of one of the most promising therapeutic targets in LDL cholesterol (LDL-C) management, proprotein convertase subtilisin/kexin type 9 (PCSK9).
Stefano, Spolitu +3 more
openaire +2 more sources
Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9 [PDF]
Journal of Thoracic Disease, 2017 Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed.
Kazuhiko, Kotani, Maciej, Banach
openaire +2 more sources
Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults
Metabolites, 2022 Background: High levels of non-HDL cholesterol (non-HDL-C), triglycerides (TG), lipoprotein (a) (Lp(a)), and Proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as low levels of HDL-C are strongly associated with cardiovascular disease (CVD ...
Marie-Hélène Gannagé-Yared +6 more
doaj +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Медицинский совет, 2021 Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva +2 more
doaj +1 more source
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Journal of Lipid Research, 2007 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined.
Yue-Wei Qian +16 more
doaj +1 more source
P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
Artery Research, 2017 Purpose/Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are modestly but significantly associated with increased risk of total cardiovascular events.
Losif Koutagiar +7 more
doaj +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li +3 more
doaj +1 more source
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
Journal of Cardiovascular Pharmacology and Therapeutics, 2014 Proprotein convertase subtilisin/kexin 9 (PCSK9) is part of the proteinase K subfamily of subtilases and plays a key role in lipid metabolism. It increases degradation of the low-density lipoprotein receptor (LDL-R), modulates cholesterol metabolism and transport, and contributes to the production of apolipoprotein B (apoB) in intestinal cells ...
Simona, Dragan +2 more
openaire +2 more sources
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Journal of Lipid Research, 2008 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey +5 more
doaj +1 more source